Prostate-specific Antigen Density as a Proxy for Predicting Prostate Cancer Severity: Is There Any Difference between...

Area of Science:

• Urology
• Oncology
• Radiology

Background:

• Prostate-specific antigen (PSA) screening for prostate cancer can lead to overdiagnosis and unnecessary biopsies.
• PSA density (PSAD) shows potential for improving biopsy decisions, but its clinical utility requires further validation.

Purpose of the Study:

• To assess the predictive capability of PSAD in identifying clinically significant prostate cancer (CSC) using both systematic and MRI-targeted biopsy approaches.

Main Methods:

• A prospective study involving 284 patients suspected of prostate cancer at two Saudi Arabian hospitals.
• Multi-parametric MRI was used, followed by systematic and MRI-targeted biopsies for positive findings.
• PSAD was calculated using MRI-derived prostate volume and categorized into subgroups.

Main Results:

• PSAD demonstrated superior discriminant ability for MRI-targeted biopsies (AUC: 0.77) compared to systematic biopsies (AUC: 0.73).
• A PSAD cutoff of 0.07 ng/ml² achieved 97% sensitivity and 87% specificity in targeted biopsies.
• Higher PSAD levels (>0.2 ng/ml²) were associated with a greater proportion of CSC detection, and PSAD >0.15 ng/ml² showed a threefold increase in CSC probability.

Conclusions:

• PSAD is a valuable tool for predicting clinically significant prostate cancer.
• A PSAD cutoff of 0.07 ng/ml² is suggested, but interpretation should incorporate patient age and other clinical factors.